Wednesday, 22 May 2019

You are here

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time it’s filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS).


The EQUATOR trial was multicenter, phase 2 study oof 191 patients with active moderate-to-severe PsA. Patients continued their background csDMARDs and were randomized to filgotinib 200 mg or placebo orally once daily. The primary endpoint was the ACR20 response at 16 weeks.

Overall, an ACR20 response was seen in 80% of filgotinib patients but only 33% of the placebo patients (treatment difference 47% [95% CI 30·2–59·6], p<0·0001).

Safety signals were similar. The most common events were nasopharyngitis and headache. 


The TORTUGA trial was a multicenter, phase 2 trial, wherein active AS patients were randomized to receive filgotinib 200 mg or placebo orally daily for 12 weeks. The primary endpoint was the change in the ankylosing spondylitis disease activity score (ASDAS) at week 12. (Citation source:

A total of 116 AS patients were treated. The mean ASDAS change was greater (−1·47) in the filgotinib group compared with placebo (−0·57) treated patients (least squares mean difference between groups of −0·85 (95% CI −1·17 to −0·53; p<0·0001).

There were no deaths reported during the study. Other adverse events were minor and balanced between groups.

These trials suggest that JAK 1 inhibition with filgotinib is efficacious and safe for the treatment ankylosing spondylitis and psoriatic arthritis patients not responding to conventional therapies. 

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed.